<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00987974</url>
  </required_header>
  <id_info>
    <org_study_id>FMD01</org_study_id>
    <nct_id>NCT00987974</nct_id>
  </id_info>
  <brief_title>Short Term Statin Treatment and Endothelial Dysfunction Due to Ischemia and Reperfusion Injury</brief_title>
  <official_title>Short Term Statin Treatment and Endothelial Dysfunction Due to Ischemia and Reperfusion Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale:&#xD;
&#xD;
      Apart from their cholesterol lowering effects, statins have cholesterol-independent&#xD;
      pleiotropic actions, such as upregulation of 5'-ectonucleotidase and up-regulation of&#xD;
      NO-synthase that may increase tolerance against ischemia-reperfusion injury (IR-injury).&#xD;
      Several animal studies have shown reduction of IR-injury as a result of statin treatment in&#xD;
      both the heart and the kidney. Recently the investigators have shown, using Annexin A5&#xD;
      targeting after voluntary ischemic exercise to assess IR-injury, a protective effect of a 7&#xD;
      day oral rosuvastatin treatment. A three day treatment with atorvastatin however failed to&#xD;
      reduce annexin targeting.&#xD;
&#xD;
      Assessment of the flow mediated dilation of the brachial artery as measure of endothelial&#xD;
      (dys)function, is a validated model to research effects of possible protective strategies and&#xD;
      perform mechanistic experiments on IR-injury in humans in vivo.&#xD;
&#xD;
      The investigators hypothesize that pretreatment with statins can increase endothelial&#xD;
      tolerance against ischemia and reperfusion injury.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      To study the protective effect of pretreatment (both 3 day and 7 day) with rosuvastatin and&#xD;
      atorvastatin on flow mediated dilation after 15 minutes ischemia and 15 minutes reperfusion.&#xD;
&#xD;
      Study design: placebo-controlled randomised double-blind trial&#xD;
&#xD;
      Study population: Healthy volunteers, age 18-50&#xD;
&#xD;
      Intervention: Treatment with either rosuvastatin 20 mg, atorvastatin 80mg or placebo during&#xD;
      either 3 or 7 days&#xD;
&#xD;
      Main study parameters: Difference in flow mediated dilation before and after 15 minutes&#xD;
      ischemia.&#xD;
&#xD;
      Nature and extent of the burden and risks associated with participation, benefit and group&#xD;
      relatedness: Treatment with rosuvastatin or atorvastatin is not expected to harm the&#xD;
      volunteers. Most reported side effects of rosuvastatin and atorvastatin are gastro-intestinal&#xD;
      complains and myalgia. The volunteers will not benefit directly from participating in this&#xD;
      study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in flow mediated dilation before and after 15 minutes ischemia</measure>
    <time_frame>30 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ecto-5'-nucleotidase activity and lipid profile after statin therapy</measure>
    <time_frame>3-7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Ischemia Reperfusion Injury</condition>
  <condition>Endothelial Dysfunction</condition>
  <arm_group>
    <arm_group_label>rosuvastatin 3days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 Subjects will use rosuvastatin 20 mg/day for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>atorvastatin 3 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>8 Subjects will use atorvastatin 80 mg/day for 3 days.pj</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo 3days</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>8 Subjects will use placebo for 3 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rosuvastatin 7 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 Subjects will use rosuvastatin 20 mg/day for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>atorvastatin 7 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>8 Subjects will use atorvastatin 80 mg/day for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo 7 days</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>8 Subjects will use placebo for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rosuvastatin</intervention_name>
    <description>rosuvastatin 20 mg/day for 3 days.</description>
    <arm_group_label>rosuvastatin 3days</arm_group_label>
    <other_name>crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin 3 days</intervention_name>
    <description>atorvastatin 80 mg/day for 3 days.</description>
    <arm_group_label>atorvastatin 3 days</arm_group_label>
    <other_name>lipitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo for 3 days.</description>
    <arm_group_label>placebo 3days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rosuvastatin 7 days</intervention_name>
    <description>rosuvastatin 20 mg/day for 7 days</description>
    <arm_group_label>rosuvastatin 7 days</arm_group_label>
    <other_name>crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin 7 days</intervention_name>
    <description>atorvastatin 80 mg/day for 7 days.</description>
    <arm_group_label>atorvastatin 7 days</arm_group_label>
    <other_name>lipitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo 7 days</intervention_name>
    <description>placebo 7 days</description>
    <arm_group_label>placebo 7 days</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-50&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  History of any cardiovascular disease&#xD;
&#xD;
          -  Hypertension (in supine position: systole &gt;140 mmHg, diastole &gt;90 mmHg)&#xD;
&#xD;
          -  Diabetes Mellitus (fasting glucose &gt;7.0 mmol/L or random glucose &gt;11.0 mmol/L)&#xD;
&#xD;
          -  Hyperlipidaemia (fasting total cholesterol &gt;5.5 mmol/L or random cholesterol &gt;6.5&#xD;
             mmol/L)&#xD;
&#xD;
          -  Alanine amino transferase &gt;90 U/L&#xD;
&#xD;
          -  Creatine kinase &gt;440 U/L&#xD;
&#xD;
          -  Raised rhabdomyolysis risk&#xD;
&#xD;
               -  GFR &lt;60 ml/min&#xD;
&#xD;
               -  Overt clinical signs of hypothyroidism&#xD;
&#xD;
               -  Myopathy in family history&#xD;
&#xD;
               -  Alcohol abuse&#xD;
&#xD;
          -  Concomitant chronic use of medication&#xD;
&#xD;
          -  Participation to any drug-investigation during the previous 60 days as checked with&#xD;
             VIP check.&#xD;
&#xD;
          -  Professional athletes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>RUNMC</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Meijer P, Oyen WJ, Dekker D, van den Broek PH, Wouters CW, Boerman OC, Scheffer GJ, Smits P, Rongen GA. Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection. Arterioscler Thromb Vasc Biol. 2009 Jun;29(6):963-8. doi: 10.1161/ATVBAHA.108.179622. Epub 2009 Apr 9.</citation>
    <PMID>19359665</PMID>
  </reference>
  <reference>
    <citation>Kharbanda RK, Peters M, Walton B, Kattenhorn M, Mullen M, Klein N, Vallance P, Deanfield J, MacAllister R. Ischemic preconditioning prevents endothelial injury and systemic neutrophil activation during ischemia-reperfusion in humans in vivo. Circulation. 2001 Mar 27;103(12):1624-30.</citation>
    <PMID>11273988</PMID>
  </reference>
  <verification_date>April 2001</verification_date>
  <study_first_submitted>September 30, 2009</study_first_submitted>
  <study_first_submitted_qc>September 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2009</study_first_posted>
  <last_update_submitted>April 27, 2010</last_update_submitted>
  <last_update_submitted_qc>April 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>G. Rongen</name_title>
    <organization>RUNMC</organization>
  </responsible_party>
  <keyword>ischemia reperfusion injury</keyword>
  <keyword>endothelial dysfunction</keyword>
  <keyword>statins</keyword>
  <keyword>rosuvastatin</keyword>
  <keyword>atorvastatin</keyword>
  <keyword>placebo</keyword>
  <keyword>ecto-5'-nucleotidase</keyword>
  <keyword>flow mediated dilation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Reperfusion Injury</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

